Search research articles
Contact Us
Filters
Showing results (131-140 of 157) with videos related to
Page
of 16
Sort By:
Nature Communications
|
June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 20, 2021
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, et al.
Cancer Immunology, Immunotherapy : CII
|
March 9, 2026
Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures
Annastasia Petouhoff, Ryan Hicks, Marium Husain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready, Matthew D Hellmann, Mark M Awad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)
Dara L Aisner, Lynette M Sholl, Lynne D Berry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
The Lancet. Oncology
|
February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A Rizvi, Julien Mazières, David Planchard, et al.
Cancer Medicine
|
July 28, 2025
Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies
Mingjia Li, Po-Lan Su, Songzhu Zhao, et al.
JCO Precision Oncology
|
February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor
Jonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 14, 2015
Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines
Douglas E Wood, Ella Kazerooni, Scott L Baum, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 157) with videos related to
Sort By:
Page
of 16
Nature Communications
|
June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 20, 2021
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, et al.
Cancer Immunology, Immunotherapy : CII
|
March 9, 2026
Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures
Annastasia Petouhoff, Ryan Hicks, Marium Husain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready, Matthew D Hellmann, Mark M Awad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)
Dara L Aisner, Lynette M Sholl, Lynne D Berry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
The Lancet. Oncology
|
February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A Rizvi, Julien Mazières, David Planchard, et al.
Cancer Medicine
|
July 28, 2025
Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies
Mingjia Li, Po-Lan Su, Songzhu Zhao, et al.
JCO Precision Oncology
|
February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor
Jonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 14, 2015
Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines
Douglas E Wood, Ella Kazerooni, Scott L Baum, et al.
Page
of 16